Abstract
Purpose: To formulate and characterize tablets containing Pitavastatin that have been loaded with a self-nano emulsifying drug delivery system (SNEDDS).
Methods: Pitavastatin SNEDDS were prepared with a variety of oils, surfactants, co-surfactants, and solvents to improve the dissolution rate and bioavailability of the HMG-CoA reductase inhibitor. The SNEDDS components were preliminarily investigated for drug solubility in various vehicles, excipient miscibility, emulsification rate, and ternary phase diagrams. The tablets were made using a porous carrier made of Aerosil 200 and then loaded with SNEDDS using a simple absorption method. Physical parameters such as tablet hardness, weight variation, disintegration, drug content, and in-vitro drug release were then measured on the tablets.
Results: Labrafac Lipophilewl1349 (Oil), Tween 80 (Surfactant) and Egg lecithin (Co-surfactant) were selected for the preparation of SNEDDS. Tablets with high porosity suitable for loading with SNEDDS and containing the super-disintegrants, achieved complete dissolution of Pitavastatin from the tablets. In vitro release of Pitavastatin from SNEDDS and the tablets was similar (p < 0.05).
Conclusion: SNEDDS of Pitavastatin is a promising approach to achieving a solid dosage form of the liquid-loaded drug delivery systems for enhancing the solubility and dissolution rate of the drug, and hence also its bioavailability.
Keywords: Pitavastatin, drug carrier, SNEDDS, self-nanoemulsifying, solubility, drug release, surfactant, co-surfactant.
Graphical Abstract
[http://dx.doi.org/10.1016/j.ejps.2007.05.110] [PMID: 17616376]
[http://dx.doi.org/10.1016/j.powtec.2017.12.066]
[http://dx.doi.org/10.1016/S0939-6411(00)00089-8] [PMID: 10840200]
[http://dx.doi.org/10.1016/j.ijpharm.2013.03.054] [PMID: 23578826]
[http://dx.doi.org/10.1016/j.ijpharm.2016.10.052]
[http://dx.doi.org/10.1016/j.jddst.2015.07.003]
[http://dx.doi.org/10.1016/j.jcis.2016.09.003] [PMID: 27657837]
[http://dx.doi.org/10.2478/v10007-008-0016-1] [PMID: 19103563]
[http://dx.doi.org/10.1016/j.addr.2007.05.006] [PMID: 17618704]
[http://dx.doi.org/10.1016/S0169-409X(96)00490-5]
[http://dx.doi.org/10.1016/S0928-0987(00)00167-6] [PMID: 11033431]
[PMID: 24511474]
[http://dx.doi.org/10.1016/j.jddst.2018.03.020]
[http://dx.doi.org/10.3109/03639045.2014.886695] [PMID: 24517575]
[http://dx.doi.org/10.1517/17425247.2014.877885] [PMID: 24386966]
[http://dx.doi.org/10.1016/j.ijpharm.2015.09.011] [PMID: 26364711]
[http://dx.doi.org/10.4103/1735-5362.213986] [PMID: 28974979]
[http://dx.doi.org/10.4103/1735-5362.235156] [PMID: 30065762]
[http://dx.doi.org/10.1016/j.ejpb.2016.04.008] [PMID: 27091783]
[http://dx.doi.org/10.1016/j.ijpharm.2011.09.007] [PMID: 21944892]
[http://dx.doi.org/10.1590/s2175-97902018000117232]
[http://dx.doi.org/10.1038/srep46517] [PMID: 28462948]
[http://dx.doi.org/10.1016/j.jpba.2011.05.008] [PMID: 21652159]
[http://dx.doi.org/10.1080/17425247.2016.1218462] [PMID: 27485144]
[http://dx.doi.org/10.1016/j.ijpharm.2012.04.001] [PMID: 22498011]
[http://dx.doi.org/10.1080/03601234.2017.1362941] [PMID: 29111904]
[http://dx.doi.org/10.1016/j.jconrel.2017.03.008] [PMID: 28279798]
[http://dx.doi.org/10.1016/j.cocis.2016.03.002]
[http://dx.doi.org/10.1016/j.cocis.2012.07.003]
[http://dx.doi.org/10.1208/s12249-014-0078-y] [PMID: 24452500]
[http://dx.doi.org/10.1016/j.ijpharm.2017.10.017] [PMID: 29038063]
[http://dx.doi.org/10.3109/10717544.2013.878003] [PMID: 24512268]
[http://dx.doi.org/10.15171/apb.2016.052] [PMID: 27766224]
[http://dx.doi.org/10.1088/1757-899X/333/1/012064]
[http://dx.doi.org/10.1016/j.colsurfb.2017.08.050] [PMID: 28892871]
[http://dx.doi.org/10.1016/j.colsurfb.2011.04.016] [PMID: 21550214]
[http://dx.doi.org/10.3109/10837450903286537] [PMID: 19793039]
[http://dx.doi.org/10.1016/j.spl.2017.06.005]
[http://dx.doi.org/10.1016/j.ejps.2006.04.016] [PMID: 16815001]
[http://dx.doi.org/10.1016/j.ejps.2013.09.007] [PMID: 24056027]
[http://dx.doi.org/10.1016/j.ejps.2015.03.024] [PMID: 25845633]